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Abstract. Hypoxemia is readily detectable by assessing SpO2 levels, and these are important in optimizingCOVID-19
patient management. Hyperlactatemia is a marker of tissue hypoxia, particularly in patients with increased oxygen
requirement and microvascular obstruction. We monitored peripheral venous lactate concentrations in hospitalized
patientswithmoderate to severeCOVID-19 (n=18) and inmild ambulatoryCOVID-19patients in homequarantine (n=16).
Whole blood lactate decreased significantly during the clinical course and recovery in hospitalized patients (P = 0.008).
The blood lactate levels were significantly higher in hospitalized patients than ambulatory patients (day 1: hospitalized
versus ambulatory patients P = 0.002; day 28: hospitalized versus ambulatory patients P = < 0.0001). Elevated lactate
levels may be helpful in risk stratification, and serial monitoring of lactate may prove useful in the care of hospitalized
COVID-19 patients.
Severe SARS-CoV-2 causes pneumonia and hypoxemia,
often out of proportion to symptoms reported by COVID-19
patients.1 Hypoxemia is readily detectable by assessing SpO2
levels, and these are important in optimizing patient man-
agement. The degree to which systemic hypoxemia results in
tissue hypoxemia and an increase in anaerobic glycolysis is
unknown in COVID-19. Several factors could mitigate the
tissue effects of decreased oxygen diffusion capacity in the
lungs, including increased oxygen delivery by a right shift in
the oxygen–hemoglobin dissociation curve (Bohr effect), in-
creased fractional unloading of oxygen, and increased he-
moglobin concentrations. Hyperlactatemia is one marker of
tissue hypoxia, particularly when anaerobic tissue metab-
olism is increased in infections where there is anemia, fever
with increased oxygen requirement, and microvascular
obstruction. Severe malaria exemplifies these predisposi-
tions, and increased lactate levels (³ 5 mmol/L), particularly
if they are sustained after admission, are one of the best
prognostic indicators of disease severity and fatal out-
comes.2 Lactate levels are also associatedwith poor clinical
outcomes, as observed in a recent retrospective observa-
tional study in patients with COVID-19 pneumonia.3 We
monitored peripheral venous lactate concentrations in
hospitalized patients with moderate to severe COVID-19
(n = 18) and in mild ambulatory COVID-19 patients in home
quarantine (n = 16).
The study was conducted in Germany. A total of 186 hos-
pitalized patients were screened for inclusion, and 18 of them
were enrolled in the hospitalized group. The hospitalized pa-
tients were more commonly elderly, with pre-existing medical
conditions, and were on co-medications that cause adverse
interactions when taken with hydroxychloroquine (HCQ).
Hospitalized patients also showed comorbidities, especially
diabetes (59/186; 32%), renal insufficiency (53/186; 28%), and
heart failure (47/186; 25%). Of the 186 patients examined, 168
could not be recruited for various reasons (Table 1). A detailed
description of the inclusion and exclusion criteria for hospitalized
COVID-19 patients is available at the European union (EU) Reg-
ister of Clinical Studies (EudraCT-Number 2020-001224-33;
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-
001224-33/DE).
A total of 21 ambulatory patients were screened, and 16 of
those who met the inclusion criterion were enrolled. Invited to
participate in the study were ambulatory patients who were
classified as SARS-CoV2-PCR–positive by the local health
department and showed no clinical complications other than
fever and were quarantined at home. None of the ambulatory
patient reported breathing difficulties or respiratory distress
during recruitment. Of the 21 patients examined, five did not
meet the inclusion criteria because of co-medication, low
body weight, QT/QTc interval, and respiratory complications
(Table 1). A detailed description of the inclusion and exclusion
criteria for ambulatoryCOVID-19patients is available in theEU
Register of Clinical Studies (EudraCT Number: 2020 001512-
26; https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-
001512-26/DE).
The baseline patient characteristics of the COVID-19 pa-
tients are summarized in Table 2. Of the 18 hospitalized pa-
tients examined, the median age was 69 (range 28–83) years
and 63%weremale. Of the 16 examined ambulatory patients,
the median age was 43 (range 18–63) years and 44% were
male. Hospitalized patients were older than ambulatory
patients (P < 0.001). Hospitalized patients were SARS-CoV-
2–positive on day 1 and negative on day 7 (except for four
positives) on day 14, whereas all ambulatory patients were
SARS-CoV-2–positive on day 1 and became negative on day 7
and day 14 (except for two). During the clinical course of COVID-
19, one patient in the hospitalized group died (1/18), whereas
others recovered. None of the ambulatory patients had de-
veloped any clinical complications. Kidney or respiratory
failure, shock, or death was not observed in the ambulatory
patients. Furthermore, none of the ambulatory patients were
hospitalized nor required supplemental oxygen during the
follow-up period.
Both hospitalizedandambulatory patientswere followedup
longitudinally. Serum samples were collected from hospital-
ized patients on days 1, 7, 14, and 28 and from ambulatory
patients on days 1, 14, and 28. COVID-19was diagnosedwith
a RealStar® SARS-CoV-2 real-time PCR targeting the S gene
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of SARS-CoV-2 (Altona Diagnostics, Hamburg, Germany).
Lactate concentrations (assayed with Sigma-Aldrich, Saint
Louis, Missouri, on a PHOmo microplate reader, Autobio Di-
agnostics, Zhengzhou, China) were obtained on days 1, 7,
14, and 28 in hospitalized patients, and on days 1, 14, and
28 in ambulatory patients. The nonparametric Friedman
test was used to detect differences in the analysis of vari-
ance with repeated measurements (SPSS Statistics, IBM,
Armonk, NY).
Median whole blood lactate levels in hospitalized patients
were d1 = 3.3, d7 = 2.6, d14 = 2.2, d28 = 1.9 mmol, and in
ambulatory patients, d1 = 1.4, d14 = 1.4, d28 = 1.5 mmol.
Whole blood lactate decreased significantly during the clinical
course and recovery in hospitalized patients (P = 0.008). The
blood lactate levels were significantly higher in hospitalized
patients than ambulatory patients (day 1: hospitalized versus
ambulatory patients P = 0.002; day 28: hospitalized versus
ambulatory patients P = < 0.0001).
TABLE 1
Clinical characteristics of hospitalized and ambulatory COVID-19 patients during recruitment
COVID-19 patient Hospitalized (18/186) Ambulatory (16/21)
Patients screened 186 21
Patients fulfill inclusion criteria 18 17
Patients who did not consent/eligible to be included 168 5
Exclusion criterion (as below) 70 4
Severe cardiac failure 1 –
Cardiological risk profile 0 1
Delirium and QT prolongation 1 –
Dementia 15 –
Low body weight 1 1
HCQ as co-medication 4 –
ICU and respiratory failure or hemodynamic instability 9 –
ICU and HCQ as co-medication 1 –
ICU and QT prolongation 2 –
Cognitive impairment 2 –
Percutaneous endoscopic gastrostomy 2 –
QT prolongation 8 2
Hematological disease 1 –
Hemato-oncological disease 12 –
Hemato-oncological disease and dementia 1 –
Hemato-oncological disease and cognitive impairment 1 –
Hemato-oncological disease and myocardial infarction 1 –
Hemato-oncological disease and QT prolongation 1 –
Myasthenia gravis 1 –
Retinopathy/macular degeneration 3 –
Retinopathy/macular degeneration and bradyarrhythmia 1 –
Retinopathy/macular degeneration and ICU 1 –
Retinopathy/macular degeneration and QT prolongation and dementia 1 –
HCQ = hydroxychloroquine; ICU = intensive care unit.
TABLE 2
Baseline characteristics of hospitalized and ambulatory COVID-19 patients
COVID-19 patient characteristic Hospitalized (n = 18) Ambulatory (n = 16) P-value
Median age (range) 69 (28–83) 43 (18–63) < 0.0001
Male (n) (%) 12 (63%) 7 (44%) NS
Median blood pressure (systolic/diastolic) 135/74 143/92 NS
Median respiratory rate (breaths/minute) (SD) 20 (± 2.7) 18 (± 3.1) NS
Median heart rate (beats per minute) (SD) 80 (± 9.8) 71 (± 17.5) NS
Geometric mean (range minimum. –maximum)
Leukocyte (n/μL) 6,139 (3,230–12,300) NA –
Neutrophils (%) 67 (36–82) NA –
Lymphocytes (%) 19 (8–49) NA –
Monocytes (%) 9 (2–14) NA –
Eosinophils (%) 0 (0–4) NA –
Basophils (%) 0.5 (0.1–1.3) NA –
Erythrocytes (million/μL) 4 (3–6) NA –
Hematocrit (%) 37 (28–47) NA –
Hb (g/dL) 12.7 (8–16) NA –
Thrombocytes (1,000/μL) 233 (105–572) NA –
Fibrinogen (mg/dL)* 472 (211–768) NA –
Procalcitonin (ng/mL) 0.09 (0.01–2.56) NA –
Creatine kinase (U/L) 93 (19–2,468) NA –
AST (U/L) 39 (17–748) NA –
ALT (U/L) 31 (9–401) NA –
LDH (U/L) 295 (153–899) NA –
AST=aspartateAminotransferase;ALT=alanine aminotransferase; LDH= lactatedehydrogenase;NA=not available;NS=nonsignificant asmildCOVID-19wasobserved in ambulatory patients
without clinical complications.
* Fibrinogen levels not available for one hospitalized patient.
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Lactate levels in patients with COVID-19 were significantly
higher in hospitalized patients with more severe disease than
ambulatory patients havingmild disease, with levels declining
over weeks in hospitalized patients. At day 28, lactate levels
were comparable between hospitalized patients and ambu-
latory patients. Four hospitalized patients with SARS-CoV-2
virus positivity on day 7 took a longer time to clear the virus
than other hospitalized patients and had consistently elevated
lactate levels (Figure 1).
Lactate levels in our hospitalized patients were moderately
elevated compared with pneumonia caused by non–SARS-
CoV-2 infections, where more severe disease (CURB-65 ³ 4)
had a median lactate level of around 4 mmol/L.4 In severe
systemic infections such as malaria, admission lactate levels
are also elevated with cutoffs > 5 mmol/L associated with
severe disease and fatal outcomes, particularly if sustained for
hours. The time courseof decreases in lactate levels inCOVID-
19 reflects a longer courseof illness. In somepatients, the lactate
level increased at D28, perhaps reflecting increased activity
when diffusion defects in lungs may not have recovered fully.
Elevations in lactate levels reflect different pathophysiological
processes with decreased oxygen diffusion in the lungs of pa-
tients with COVID-19 pneumonia, perhaps with adequate tissue
oxygenation beingmaintained inmany patients until the disease
progresses in severity (“silent hypoxia”),5,6 whereas in malaria,
tissue hypoxia caused by microvascular obstruction increases
lactate production in the host tissues.7
A total of 10% of hospitalized patients could only be
recruited, asmany of the hospitalized patients do not fulfill the
inclusion criteria, that includes denial of informed written
consent. This is acknowledged as a major limitation in this
study. Although age and concurrent comorbidities of COVID-
19 patients largely determine the COVID-19 clinical course,8,9
elevated lactate levels equally facilitate the assessment of
disease course.
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FIGURE 1. Lactate levels associated with COVID-19 clinical phenotype (hospitalized patients vs. outpatients). The nonparametric Friedman test
was used to detect differences in the analysis of variance with repeatedmeasurements. Figures were created using ggplot2 package version 3.2.1
supported on R program software version 3.5.0.
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